What we do Sahajanand Medical Technologies designs, manufactures and markets vascular medical devices globally, specializing in interventional cardiology, structural heart therapy and peripheral intervention products. |
Founded in 2,001 |
Market share Leading medical devices firm with strong presence in 69+ countries, noted for quality and innovation in vascular devices. |
Problem solved Develops life-saving vascular devices to address critical heart and peripheral vascular conditions, improving patient outcomes worldwide. |
Top clients or who we serve Hospitals and healthcare providers worldwide; primarily B2B with direct and distributor sales in 69+ countries. |
Key management - |
Our journey and innovations Founded 2001; introduced revolutionary biodegradable polymer drug-eluting stents in 2005; expanded internationally and diversified into structural heart therapy by 2020. |
Where we operate Direct operations in 10 countries including Germany, Poland, Brazil; distributor network spans over 59 countries. |
Top products or what we offer Flagship products include coronary stents like Supraflex Cruz, renal stents Renofit, and transcatheter valve implants in structural heart therapy. |
Top brands Supraflex Cruz - widely recognized coronary stent; Renofit - cobalt chromium renal stent; diversified device portfolio expanded via acquisitions. |
Raw materials needed - |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue primarily from product sales, cyclical with demand from healthcare sector advancements. |
Our industry position Pioneer in vascular devices in India with significant global footprint and innovation leadership in stent technology. |
Financial highlights Revenue Rs. 1210.5 crore, Net Profit Rs. 65.29 crore for year ending 2026; showing steady growth and strong margins. |
Geographical revenue split Approx. 26% revenue from India and 58% from outside India markets as of fiscal year 2025. |
Order book - |
Whats driving growth New product launches, international expansion, strategic acquisitions, and strong clinical data supporting device efficacy. |
Our future plans Increase global direct presence, expand product range especially in structural heart therapy, and strengthen R&D pipeline. |
Our green promise - |
Our people and values - |
Key challenges ahead Competition in global vascular devices market and need for continual innovation to sustain growth and market share. |
Interesting facts First Indian company to launch biodegradable polymer drug-eluting stents and one of the lowest strut thickness stents worldwide. |
Risks and strategy Market competition and regulatory risks managed through innovation, quality focus, and expanding diversified international footprint. |
